|
1
|
Łabno A, Tomecki R and Dziembowski A:
Cytoplasmic RNA decay pathways-Enzymes and mechanisms. Biochim
Biophys Acta. 1863:3125–3147. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Derrigo M, Cestelli A, Savettieri G and Di
Liegro I: RNA-protein interactions in the control of stability and
localization of messenger RNA (Review). Int J Mol Med. 5:111–123.
2000.PubMed/NCBI
|
|
3
|
Hinman MN and Lou H: Diverse molecular
functions of Hu proteins. Cell Mol Life Sci. 65:3168–3181. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gately S and Li WW: Multiple roles of
COX-2 in tumor angiogenesis: A target for angiogenenic therapy.
Semin Oncol 31 (2 Suppl 7). 2–11. 2004.
|
|
5
|
Sakuma T, Nakagawa T, Ido K, Takeuchi H,
Sato K and Kubota T: Expression of vascular endothelial growth
factor-A and mRNA stability factor HuR in human meningiomas. J
Neurooncol. 88:143–155. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lim SJ, Lee SH, Joo SH, Song JY and Choi
SI: Cytoplasmic expression of HuR is related to cyclooxygenase-2
expression in colon cancer. Cancer Res Treat. 41:87–92. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yuan Z, Sanders AJ, Ye L, Wang Y and Jiang
WG: Prognostic value of human antigen R (HuR) in human breast
cancer: High level predicts a favourable prognosis. Anticancer Res.
31:303–310. 2011.PubMed/NCBI
|
|
8
|
Miyata Y, Watanabe S, Sagara Y, Mitsunari
K, Matsuo T, Ohba K and Sakai H: High expression of HuR in
cytoplasm, but not nuclei, is associated with malignant
aggressiveness and prognosis in bladder cancer. PLoS One.
8:e590952013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kotta-Loizou I, Gianginis C and Theocharis
S: Clinical significance of HuR expression in human malignancy. Med
Oncol. 31:1612014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ronkainen H, Vaarala MH, Hirvikoski P and
Ristimäki A: HuR expression is a marker of poor prognosis in renal
cell carcinoma. Tumor Biol. 32:481–487. 2011. View Article : Google Scholar
|
|
11
|
Costantino CL, Witkiewicz AK, Kuwano Y,
Cozzitorto JA, Kennedy EP, Dasgupta A, Keen JC, Yeo CJ, Gorospe M
and Brody JR: The role of HuR in gemcitabine efficacy in pancreatic
cancer: HuR up-regulates the expression of the gemcitabine
metabolizing enzyme doxycytidine kinase. Cancer Res. 69:4567–4572.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
van Haperen VW Ruiz, Veerman G, Eriksson
S, Boven E, Stegmann AP, Hermsen M, Vermorken JB, Pinedo HM and
Peters GJ: Development and characterization of a
2′,2′-difluorodeoxycytidine-resistant variant of the human ovarian
cancer cell line A2780. Cancer Res. 54:4138–4143. 1994.PubMed/NCBI
|
|
13
|
Kroep JR, Loves WJ, van der Wilt CL,
Alvarez E, Talianidis I, Boven E, Braakhuis BJ, van Groeningen CJ,
Pinedo HM and Peters GJ: Pretreatment deoxycytidine kinase levels
predict in vivo gemcitabine sensitivity. Mol Cancer Ther.
1:371–376. 2002.PubMed/NCBI
|
|
14
|
Sekine S, Shimada Y, Nagata T, Moriyama M,
Omura T, Yoshioka I, Hori R, Matsui K, Sawada S, Okumura T, et al:
Establishment and characterization of a new human gallbladder
carcinoma cell line. Anticancer Res. 32:3211–3218. 2012.PubMed/NCBI
|
|
15
|
Richards NG, Rittenhouse DW, Freydin B,
Cozzitorto JA, Grenda D, Rui H, Gonye G, Kennedy EP, Yeo CJ, Brody
JR and Witkiewicz AK: HuR status is a powerful marker for prognosis
and response to gemcitabine-based chemotherapy for resected
pancreatic ductal adenocarcinoma patients. Ann Surg. 252:499–506.
2010.PubMed/NCBI
|
|
16
|
Maréchal R and van Laethem JL: HuR
modulates gemcitabine efficacy: New perspectives in pancreatic
cancer treatment. Expert Rev Anticancer Ther. 9:1439–1441. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kamat AM, Hahn NM, Efstathiou JA, Lerner
SP, Malmström PU, Choi W, Guo CC, Lotan Y and Kassouf W: Bladder
cancer. Lancet. Jun 23–2016.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sternberg CN, Yagoda A, Scher HI, Watson
RC, Ahmed T, Weiselberg LR, Geller N, Hollander PS, Herr HW and
Sogani PC: Preliminary results of M-VAC (methotrexate, vinblastine,
doxorubicin and cisplatin) for transitional cell carcinoma of the
urothelium. J Urol. 133:403–407. 1985.PubMed/NCBI
|
|
19
|
von der Maase H, Hansen SW, Roberts JT,
Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A,
Lippert CM, et al: Gemicitabine and cisplatin versus methotrexate,
vinblastine, doxorubicin, and cisplatin in advanced or metastatic
bladder cancer: Results of a large, randomized, multinational,
multicenter, phase III study. J Clin Oncol. 18:3068–3077.
2000.PubMed/NCBI
|
|
20
|
Saxman SB, Propert KJ, Einhorn LH,
Crawford ED, Tannock I, Raghavan D, Loehrer PJ Sr and Trump D:
Long-term follow-up of a phase III intergroup study of cisplatin
alone or in combination with methotrexate, vinblastine, and
doxorubicin in patients with metastatic urothelial carcinoma: A
cooperative group study. J Clin Oncol. 15:2564–2569.
1997.PubMed/NCBI
|
|
21
|
von der Maase H, Sengelov L, Roberts JT,
Ricci S, Dogliotti L, Oliver T, Moore MJ, Zimmermann A and Arning
M: Long-term survival results of a randomized trial comparing
gemcitabine plus cisplatin, with methotrexate, vinblastine,
doxorubicin, plus cisplatin in patients with bladder cancer. J Clin
Oncol. 23:4602–4608. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Miyata Y, Asai A, Mitsunari K, Matsuo T,
Ohba K and Sakai H: Safety and efficacy of combination therapy with
low-dose gemcitabine, paclitaxel, and sorafenib in patients with
cisplatin-resistant urothelial cancer. Med Oncol. 32:2352015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Massari F, Santoni M, Ciccarese C,
Brunelli M, Conti A, Santini D, Montironi R, Cascinu S and Tortora
G: Emerging concepts on drug resistance in bladder cancer:
Implications for future strategies. Crit Rev Oncol Hematol.
96:81–90. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Stadler WM, Kuzel T, Roth B, Raghavan D
and Dorr FA: Phase II study of single-agent gemcitabine in
previously untreated patients with metastatic urothelial cancer. J
Clin Oncol. 15:3394–3398. 1997.PubMed/NCBI
|
|
25
|
Miyata Y, Nomata K, Ohba K, Matsuo T,
Sagara Y, Kanetake H and Sakai H: Use of low-dose combined therapy
with gemcitabine and paclitaxel for advanced urothelial cancer
patients with resistance to cisplatin-containing therapy: A
retrospective analysis. Cancer Chemother Pharmacol. 70:451–459.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kim MY, Hur J and Jeong S: Emerging roles
of RNA and RNA-binding protein network in cancer cells. BMB Rep.
42:125–130. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mitsunari K, Miyata Y, Asai A, Matsuo T,
Shida Y, Hakariya T and Sakai H: Human antigen R is positively
associated with malignant aggressiveness via upregulation of cell
proliferation, migration, and vascular endothelial growth factors
and cyclooxygenase-2 in prostate cancer. Transl Res. 175:116–128.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Pineda DM, Rittenhouse DW, Valley CC,
Cozzitorto JA, Burkhart RA, Leiby B, Winter JM, Weber MC, Londin
ER, Rigoutsos I, et al: HuR's post-transcriptional regulation of
death receptor 5 in pancreatic cancer cells. Cancer Biol Ther.
13:946–955. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bellmunt J and Albiol S: Chemotherapy for
metastatic or unresectable bladder cancer. Semin Oncol. 34:135–144.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Prislei S, Martinelli E, Mariani M,
Raspaglio G, Sieber S, Ferrandina G, Shahabi S, Scambia G and
Ferlini C: MiR-200c and HuR in ovarian cancer. BMC Cancer.
13:722013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang J, Li D, Wang B and Wu Y: Predictive
and prognostic significance of cytoplasmic expression of ELAV-like
protein HuR in invasive breast cancer treated with neoadjuvant
chemotherapy. Breast Cancer Res Treat. 141:213–224. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li Y, Yu J, Du D, Fu S, Chen Y, Yu F and
Gao P: Involvement of post-transcriptional regulation of FOXO1 by
HuR in 5-FU-induced apoptosis in breast cancer cells. Oncol Lett.
6:156–160. 2013.PubMed/NCBI
|
|
34
|
Latorre E, Tebaldi T, Viero G, Spartà AM,
Quattrone A and Provenzani A: Downregulation of HuR as a new
mechanism of doxorubicin resistance in breast cancer cells. Mol
Cancer. 11:132012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lal S, Burkhart RA, Beeharry N,
Bhattacharjee V, Londin ER, Cozzitorto JA, Romeo C, Jimbo M, Norris
ZA, Yeo CJ, et al: HuR posttranscriptionally regulates WEE1:
Implication for the DNA damage response in pancreatic cancer cells.
Cancer Res. 74:1128–1140. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Raspaglio G, De Maria I, Filippetti F,
Martinelli E, Zannoni GF, Prislei S, Ferrandina G, Shahabi S,
Scambia G and Ferlini C: HuR regulates beta-tubulin isotype
expression in ovarian cancer. Cancer Res. 70:5891–5900. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang J, Li D, Wang B and Wu Y: Predictive
and prognostic significance of cytoplasmic expression of ELAV-like
protein HuR in invasive breast cancer treated with neoadjuvant
chemotherapy. Breast Cancer Res Treat. 141:213–224. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Williams TK, Costantino CL, Bildzukewicz
NA, Richards NG, Rittenhouse DW, Einstein L, Cozzitorto JA, Keen
JC, Dasgupta A, Gorospe M, et al: pp32 (ANP32A) expression inhibits
pancreatic cancer cell growth and induces gemcitabine resistance by
disrupting HuR binding to mRNAs. PLoS One. 5:e154552010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Imamachi K, Higashino F, Kitamura T,
Kakuguchi W, Yanagawa-Matsuda A, Ishikawa M, Kitagawa Y, Totsuka Y
and Shindoh M: pp32r1 controls the decay of the RNA-binding protein
HuR. Oncol Rep. 31:1103–1108. 2014.PubMed/NCBI
|
|
40
|
Miyata Y, Mitsunari K, Akihiro A, Watanabe
SI, Mochizuki Y and Sakai H: Smoking-induced changes in
cancer-related factors in patients with upper tract urothelial
cancer. Mol Clin Oncol. 3:287–294. 2015.PubMed/NCBI
|
